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Tryptase Mast Cells in Malignant Pleural Mesothelioma as
an Independent Favorable Prognostic Factor
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Valentina Corsi, BS,* and Gabriella Fontanini, MD*
Introduction: Malignant pleural mesothelioma is a highly aggres-
sive neoplasm with an incidence that is increasing world-wide. Mast
cells are part of the innate immune system and have been associated
with different solid tumors, but there is controversy surrounding
their pro- and antitumorigenic effects in cancers. There are two
subsets of human mast cells, resulting from the expression of
different enzymes: tryptase positive mast cells and chymase positive
mast cells. The purpose of this study was to determine the presence
and prognostic significance of tumor infiltrating mast cells in me-
sothelioma.
Methods: Tryptase and chymase mast cell counts were determined
by immunohistochemistry in 60 patients with mesothelioma. All
pathologic samples were from patients who underwent treatment
with intrapleural preoperative interleukin-2 (18  106 IU/d for 3
days). After one day of recovery, patients underwent surgery.
Pleural samples were also immunostained for CD34 to evaluate
microvessel count.
Results: High tryptase mast cells counts were found in the majority
(73.3%) of the cases studied, and the results were significantly
associated with both overall survival (p  0.02) and time to
progression (p  0.01). This finding was confirmed using multivar-
iate analysis: a higher tryptase mast cells count emerged as an
independent favorable prognostic factor (p  0.02). However,
tryptase mast cells count did not show significant correlation with
microvessel count.
Conclusions: These results suggest that tumor infiltrating tryptase
mast cells, after interleukin-2 preoperative induction therapy, predict
improved clinical outcome in patients with malignant pleural me-
sothelioma, and highlight the critical role of the local inflammatory
response in mesothelioma cancer progression.
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Malignant pleural mesothelioma (MPM) is a highly ag-gressive and relatively rare tumor whose frequency is
increasing throughout the world. The median survival is now
12 months from onset of symptoms,1 leaving a poor progno-
sis for the patient. There is no standard therapy for MPM,
although recent reports suggest that multimodality therapy,
including surgery, may result in a significant improvement in
survival in selected patients.2,3
Like other solid tumors, MPM is an immunogenic
tumor, but the immune response is normally weak and unable
to destroy the neoplasm. Various studies have shown a
sensitivity of the mesothelioma to immunotherapy using
cytokine and adjuvant therapy in an attempt to boost the
antitumoral immune response.1
The precise role of the immune system cells around and
within the tumors is still unknown. The inflammatory infil-
trate resulting from the host’s response to the malignancy
could lead to either negative or positive effects on the tumor,
by preventing tumor progression or supporting tumor growth
by producing factors that induce angiogenesis and inhibit
apoptosis.
In a previous study, Hegmans et al.4 characterized,
using immunohistochemistry, the inflammatory component in
tumor tissue obtained from four patients with mesothelioma.
Numerous immune effector cells infiltrated mesothelioma
tissue, mostly represented by macrophages, natural killer
cells, and T-lymphocytes, whereas chymase mast cells were
absent.
Mast cells (MCs) form an important part of the inflam-
matory infiltrate associated with tumors and are found in
many tumor types, including breast,5–7 lung,8,9 ovarian,10
gastric,11 and colorectal12 cancers. MCs are usually separated
into two subsets, tryptase and chymase MCs, on the basis of
different type and amount of enzymes expressed, and the
phenotype of the MCs can vary widely in different tissue
microenvironments.9 Several studies have shown the role of
MCs in the enhancement of tumor growth and progression
through the promotion of angiogenesis.8 The mediators
present in mast cell granules include basic fibroblast growth
factor, interleukin 4 (IL 4), IL 8, and tumor necrosis factor 
and , all of which are strong inducers of angiogenesis.13
However, the MCs in tumors have been also associated with
the inhibition of tumor growth and progression, likely due to
a cytotoxic effect on tumor cells.14
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This dual and opposite relationship between MCs and
cancer needs to be further investigated. Moreover, the pres-
ence of MCs in mesothelioma has still not been elucidated.
The purpose of this study was to determine the presence
and the subset of tumor infiltrating MCs, and whether direct
correlations exist between the number of MCs and the degree
of angiogenesis, and the number of MCs and the clinical
outcome of patients with mesothelioma.
PATIENTS AND METHODS
Patients
Sixty mesothelioma specimens were obtained from
patients (51 males and 9 females) who consecutively under-
went surgical resection at the Department of Cardio-Thoracic
Surgery of the University of Pisa, from January 1999 to July
2005. Participation in this study required informed consent.
No patient had received chemotherapy or radiotherapy before
surgery. As previously reported,3 all patients received preop-
erative immunotherapy with intrapleural IL-2 (18 106 IU/d
for 3 days). After one day of recovery, all patients underwent
a thoracotomy. Of the 60 patients, 53 (88.3%) had a pleurec-
tomy/decortication (P/D), whereas the remaining 7 patients
(11.7%) had extrapleural pneumonectomy. Clinical informa-
tion, including patient gender, age, Eastern Cooperative On-
cology Group (ECOG) performance status, and local and/or
systemic recurrences, were reviewed for each patient. Pa-
tients were observed until death or the final date of analysis
(August 2008), with a median follow-up time of 74 months
for living patients (range, 2–113 months). Forty-one (68.3%)
patients presented a relapse during follow-up: 33 had a local
relapse, 7 had both a local and a systemic relapse, and only 1
patient had a systemic relapse. At the end of the follow-up
period, 15 patients (25%) were still alive and 45 (75%) had
died. Time to progression and overall survival rates were
calculated as the period from surgery until the date the
disease started to worsen (local and/or systemic recurrences),
or date of death.
Tumor Specimens
All tumor samples were formalin-fixed and paraffin-
embedded for microscopic examination. The most represen-
tative paraffin block of tumor was selected for immunohis-
tochemical analysis. Histologic diagnosis and pathologic
features were reviewed by two pathologists (G.A. and G.F.)
according to the World Health Organization 2004 histologic
and immunohistochemical criteria.15 Disagreements concern-
ing histologic diagnosis were discussed, and after a critical
discussion, mutual agreement was reached. Surgical-patho-
logic staging was performed according to tumor, node, me-
tastasis classification by the International Mesothelioma In-
terest Group (IMIG).16
Immunohistochemistry
Immunohistochemical analyses were performed on 3
m tissue sections using specific antibodies. Immunoreaction
was displayed using the avidin–biotin–peroxidase complex
method. Peroxidase activity was visualized with diaminoben-
zidine. Counterstaining was performed with hematoxylin.
Negative controls were carried out by omitting the primary
antibodies. Immunostaining was done using a Benchmark
immunostainer (Ventana, Tuscon, AZ). In all cases, the
immunohistochemical evaluation was independently per-
formed by 2 pathologists (G.A. and G.F.), who were blinded
to the clinicopathological characteristics of the patients. In all
discordant cases, mutual agreement was reached.
For tryptase and chymase immunohistochemical stain-
ings, two serial sections were incubated with a mouse anti-
human tryptase monoclonal antibody (Chemicon Interna-
tional, Temecula, CA) used at a 1:1500 dilution, and with a
mouse antihuman chymase monoclonal antibody (Chemicon
International, Temecula, CA) used at 1:1600 dilution. Immu-
nostaining for tryptase and chymase was clearly visible as
brown deposits within intact MCs and as highly localized
extracellular granular material (Figure 1). Each pathologist
identified under low microscopic power (10 objective lens
and 10 ocular lens) the areas where the MCs were most
intensely accumulated, and then counted chymase and
tryptase positive MCs at 200 microscopic fields. The aver-
age of their counts in three fields was calculated as previously
described.8 Tumor sections with no immunoreactive MCs
were considered negative. The median value of all samples
was used as a cutoff point to distinguish low from high MCs
count.9,17
The microvessel count (MVC) was determined using
anti-CD34 antibody (Ventana Medical System, ready to use
for the Ventana automated slide stainer) to better visualize the
endothelial cells and, consequently, the microvessels. A sin-
gle microvessel was defined as any brown immunostained
endothelial cell separated from adjacent microvessels, tumor
cells, and other connective tissue elements. Samples were
examined by each pathologist, who identified the area with
the most intense vascularization (hot spot) under low micro-
scopic power (10 objective lens and 10 ocular lens). In
this area, the number of microvessels were counted and
FIGURE 1. Immunohistochemical staining for tryptase posi-
tive mast cells (MCs) in a case of biphasic mesothelioma.
Original magnification, 100. Horizontal line represents the
scale bar of 50 m.
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recorded at 200 (20 objective lens and 10 ocular lens).
Large vessels with thick, muscular walls were excluded from
the counts. The presence of a lumen was not required for
scoring as a microvessel. MVCs were categorized as a di-
chotomous variable (low versus high MVC) by using the
median value as the cut-off point to distinguish a low MVC
from a high MVC.
Statistical Analysis
All statistical analyses were carried out using Statistica
software (Stat-soft). A 2 test was used to analyze the
associations between the different variables. The a priori
level of significance was set at a p value of less than 0.05.
Univariate analysis was performed by modeling Kaplan-
Meier survival curves. Multivariate analysis was carried out
using the Cox proportional-hazard model.
RESULTS
Clinicopathologic Characteristics
The mean age of the 51 (85%) male and 9 (15%) female
patients was 61.8 years (median age, 62.5 years; range, 41–77
years). Clinicopathological characteristics of patients are
summarized in Table 1. On the basis of histologic features,
tumors were classified as epithelioid in 46 patients (76.7%),
biphasic in 9 patients (15%), and sarcomatoid in 5 patients
(8.3%). The majority of patients had IMIG stage III disease
and an ECOG performance status score of 1. Preoperative
intrapleural IL-2 was administered to all patients without
dose reduction or interruption. All patients experienced fever
during treatment and required antipyretic medication (acet-
aminophen).
Associations Between Clinicopathologic
Characteristics and Survival
Among the clinicopathologic characteristics, only the
histologic subtypes were significantly associated with overall
and disease-free survival. The sarcomatoid subtype showed a
worse overall survival (p  0.02) and a shorter time to
progression (p  0.02). No significant association was found
between survival and other clinicopathologic parameters,
such as age, gender, IMIG Stage, and ECOG performance
status. The prognostic effect of the clinicopathologic param-
eters on overall survival and time to progression, evaluated
by univariate analysis, is summarized in Table 2.
Associations Between Tryptase MCs Count and
Clinicopathologic Characteristics and Survival
Tryptase positive MCs were evaluated and detected in
all tumor samples (median, 15.0; range, 1–126.8). The
tryptase MCs count was analyzed as a dichotomous variable
using the median value to distinguish low (15) from high
(15) MCs count. High MCs counts were observed in 73.3%
(44 of 60) of the cases, and a low MCs count was observed
in the remaining 26.7% (16 of 60) (Table 2).
No significant associations were found between the
density of tryptase positive MCs and other clinicopathologic
parameters, such as age, gender, histology, performance sta-
tus, and stage (Table 3).
In univariate analysis, a statistically significant associ-
ation was found between the tryptase positive MCs count and
both overall survival (p  0.02) and time to progression (p
0.01) (Table 2). A higher tryptase positive MCs count was
significantly associated with a better overall survival and a
longer time to progression. Figures 2, 3 show Kaplan-Meier
survival plots for overall survival and time to progression,
respectively. The data were dichotomized according to the
median cell-count value.
To assess whether tumor tryptase MCs counts were an
independent predictor of survival, the Cox proportional-haz-
ard model was used to carry out multivariate analysis. After
stratifying for gender, age, histology, performance status, and
stage, the tryptase MC count maintained its independent
prognostic role (p  0.02) (Table 4).
Associations Between Chymase MCs Counts
and Clinicopathologic Characteristics and
Survival
A chymase MC count was performed in all of the cases
(median, 1; range, 0–19.3). In the tissue sections, the number
of tumor chymase MCs was lower compared with the number
TABLE 1. Clinicopathologic Features of Patients With MPM
Clinicopathologic Characteristics No. of Cases %
Age (valid n 60)
Range 41–77 yr
Median 62 yr
Gender (valid n 60)
Male 51 85
Female 9 15
IMIG Stage (valid n 57)
IB 1 1.7
II 14 24.6
III 42 73.7
Histologic subtypes (valid n 60)
Epithelioid 46 76.7
Biphasic 9 15
Sarcomatoid 5 8.3
ECOG performance status (valid n 57)
0 8 14.1
1 32 56.1
2 17 29.8
Recurrence (valid n 60)
Yes 41 68.3
Local 33 55.0
Local  Sistemic 7 11.7
Sistemic 1 1.6
No 19 31.7
Overall Survival (valid n 60)
Range 2–94 mo
Median 19 mo
Time to progression (valid n 45)
Range 1–57 mo
Median 12 mo
IMIG, International Mesothelioma interest Group; ECOG, Eastern Cooperative
Oncology Group; MPM, malignant pleural mesothelioma.
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of tryptase MCs. The chymase MCs count was also evaluated
as a dichotomous variable using the median value: 33
(55.0%) cases showed low chymase MCs count (1),
whereas 27 (45%) had a high chymase MCs count (1)
(Table 2).
A significant association was observed between the
chymase MCs count and gender (p  0.03). In fact, 77.8% (7
of 9) of females had a lower MCs count in comparison with
39.2% (20 of 51) of males (Table 3).
The chymase MCs count did not show any statistically
significant correlation with overall survival, time to progres-
sion (Table 2), or any other clinicopathologic characteristics
(Table 3).
TABLE 2. Univariate Analysis of Overall Survival and Time
to Progression in 60 Patients With Mesothelioma
Features
No. of
Patients
Overall
Survival
p
Time to
Progression
p
Age (41–77 mean 61.8) median 62.5
62 30 0.09 0.22
62 30
Gender
Male 51 0.69 0.62
Female 9
IMIG stage
IB  II 1  14 0.24 0.43
III 42
Histologic subtypes
Epithelioid 46 0.02 0.02
Biphasic 9
Sarcomatoid 5
ECOG performance status
0 8 0.22 0.09
1 32
2 17
Tryptase MCs count
Low 16 0.02 0.01
High 44
Chymase MCs count
Low 33 0.38 0.52
High 27
MVC (CD34)
Low 30 0.11 0.21
High 30
IMIG, International Mesothelioma interest Group; ECOG, Eastern Cooperative
Oncology Group; MCs, mast cells; MVC, microvessel count.
TABLE 3. Association of Tryptase and Chymase MCs and
MVC Counts With Clinicopathologic Parameters
Features
Tryptase
MCs Count p
Chymase
MCs count p
Microvessel
Count p
Age 0.45 0.58 0.43
Gender 0.05 0.03 0.27
IMIG stage 0.88 0.61 0.82
Histologic subtypes 0.84 0.57 0.001
ECOG performance status 0.1 0.44 0.08
IMIG, International Mesothelioma interest Group; ECOG, Eastern Cooperative
Oncology Group; MCs, mast cells; MVC, microvessel count.
FIGURE 2. Kaplan-Meier overall survival curves for tryptase
mast cells (MCs) counts divided into two groups above and
below the median value. Curve 1, high tryptase MC counts,
median survival 21.0 months. Curve 2, low tryptase MC
counts, median survival 12.0 months.
FIGURE 3. Kaplan-Meier time to progression curves for
tryptase mast cells (MCs) counts divided into two groups
above and below the median value. Curve 1, high tryptase
MCs counts, median time to progression 17.84 months.
Curve 2, low tryptase MCs counts, median time to progres-
sion 8.92 months.
TABLE 4. Cox-Proportional Regression Model of Overall
Survival
Variables Beta
Standard Error
of Beta t p
Gender 0.23 0.141 0.16 0.87
Age 0.10 0.137 0.76 0.45
Histology 0.06 0.132 0.42 0.68
Tryptase 0.31 0.135 2.34 0.02
Stage 0.10 0.147 0.67 0.51
Performance status 0.23 0.135 1.73 0.10
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A statistically significant association was found be-
tween chymase and tryptase MCs counts. Tumors with high
chymase MCs counts showed a higher number of tryptase
positive MCs (31.34  11.62), whereas tumors with low
chymase MCs counts had a lower number of tryptase positive
MCs (21.95  20.77) (p  0.04).
Associations Between MVC and
Clinicopathologic Characteristics and Survival
The tumor-induced vascularization was evaluated by
immunohistochemistry as the MVC in the area with the most
intense neovascularization for each tumor (median, 56.2;
range, 29.5–99.3). Using the median value (56.2) of the
whole series as the cutoff point to distinguish a low from a
high MVC, we observed that 50.0% (30 of 60) of the tumors
showed a low MVC, whereas the remaining 50% (30 of 60)
had a high MVC (Table 2).
The MVC was significantly associated with the histo-
logic subtypes of mesothelioma (p  0.001), with a higher
MVC for sarcomatoid and biphasic subtypes than for the
epithelioid subtype (Table 3).
However, no significant correlations were observed
between the MVC and other clinicopathologic characteristics
(Table 3) or patient outcome (Table 2).
The MVC showed no significant association with the
tryptase MCs count, nor with chymase MCs count in the
tumors (data not shown).
DISCUSSION
The importance of the reciprocal relationship between
inflammation and cancer is being increasingly recognized,18
but the role of the immune cells infiltrating human cancers is
still unknown. The inflammatory cells accumulating in the
tumor sites have an important impact on all the cell types
present in the tumor microenvironment, including malignant
cells, stromal cells, and extracellular-matrix components.19
Inflammatory cell recruitment may represent an attempt by
the host to suppress tumor growth, but the inflammatory
component could also promote tumorigenesis and the neo-
plastic growth.20,21
Both tryptase and chymase MCs have been detected in
different solid tumors, such as breast,5–7 lung,8,9 ovarian,10
gastric,11 and colorectal12 carcinomas. Moreover, Kankunnen
et al.7 demonstrated that tryptase positive MCs in breast
tumors were significantly more numerous in malignant le-
sions compared with benign lesions. In malignant tumors,
MCs have been shown to have dual and opposite functions,
having been related to both a better prognosis5,9,10,12 and a
worse outcome.6,8
As far as we know, this is the first study in which MCs
have been extensively investigated in MPM. We evaluated
the number of tryptase and chymase MCs in a retrospective
series of 60 patients. We analyzed MCs counts as a dichot-
omous variable using the median value as the cutoff value to
distinguish tumors with a high number of MCs from those
with a low number of MCs.9,17 Taking into account this
criterion, the number of tryptase MCs in 73.3% (44 of 60) of
the cases was high, whereas the remaining 26.7% (16 of 60)
had low numbers of tryptase MCs. With regard to chymase
MCs, we detected a lower number of positive cells (median
value 1) compared with tryptase positive cells (median value
15). In fact, we found that 43.3% (26 of 60) of the mesothe-
lioma samples had no chymase MCs. Interestingly, the sam-
ples with a high chymase MCs count (45% of cases) showed
also a high number of tryptase positive MCs (p  0.04).
In a recent study, Hegmans et al.4 characterized the
inflammatory component infiltrating mesothelioma by immu-
nohistochemistry, but no MCs were detected in the tumor
tissues. This discordance with our results could be principally
due to the lower number of samples they analyzed (only 4
cases) and to the fact that they assessed MCs using only an
antichymase antibody. This latter remark confirms the dis-
crepancy between tryptase and chymase MCs that we ob-
served in our study, and that has also been observed in
malignant breast lesions.7
All patients included in the present study received
preoperative intrapleural IL-2 immunotherapy,3 and IL-2 in-
duction could activate or attract mast cells. In a previous
work, Maggiano et al.22 suggested that human MCs express
the IL-2 receptor on their surface. Furthermore, MCs are
known to produce and release different kinds of cytokines,
including IL-2, that influence biologic processes via the
“mast cell-leukocyte cytokine cascade.”23 According to these
findings, activation of MCs could result in the release of
cytokines that promote the recruitment of eosinophils, neu-
trophils, and other effector cells. In addition, other studies24,25
presupposed that IL-2 administration induces inflammation at
the tumor site by various types of leukocytes. This recruit-
ment of immune cells could be due not only to the direct
action of IL-2 but also to an indirect effect of IL-2 through
MC activation. In our study, not all patients had the same
frequency of tumor infiltrating mast cells; if IL-2 activates
MCs, therefore, its induction seems to have different role and
significance in distinct tumor microenvironments. Indepen-
dently of IL-2 action, MCs were shown to play a significant
role in tumor progression in our series of pleural mesotheli-
oma. However, the relationship between IL-2 and MCs needs
to be further investigated to elucidate the mechanisms of their
interaction.
Concerning the associations between MCs counts and
the clinical outcome of patients, we observed a statistically
significant correlation between tryptase MCs count and both
overall survival (p  0.02) and time to progression (p 
0.01). This data was also confirmed by multivariate analysis
(p  0.02). Therefore, a high number of tryptase MCs seems
to be an independent favorable prognostic factor in pleural
mesothelioma. However, our results are in agreement with
other studies, which also found a correlation with a better
prognosis in various cancer models such as non small cell
lung cancer,9 breast cancer,5 colorectal cancer,12 and ovarian
cancer.10 These results suggest that tryptase MCs could play
an important role in the boost of host immunity against
malignant mesothelial cells. However, in some studies,6,8 the
opposite relationship between MCs and clinical outcome has
been reported. These conflicting results could be due to
different local tumoral microenvironments that could differ-
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ently influence the phenotype and function of the MCs.26,27
MCs are capable of producing angiogenic factors, such as
vascular endothelial growth factor, basic fibroblast growth
factor, and transforming growth factor-ß,28,29 as well as fac-
tors that may inhibit angiogenesis, such as protamine and
platelet factor 4.30 In vitro studies have also demonstrated that
activated MCs induced endothelial cell apoptosis.31,32 Several
studies have correlated MCs with angiogenesis in different
tumors, such as gastric,11 lung,8 and pancreatic cancer,33
whereas other reports have found no significant correlations
in ovarian and lung cancer.10,34 In the light of those studies,
we have also evaluated the MVC in our series of mesotheli-
omas and we did not find significant associations with either
tryptase or chymase MCs counts. These controversial results
could be related to several factors. First, methodological
differences for detection of inflammatory cells and vessels
can be primarily due to differences in immunohistochemical
reagents. Second, MCs have been shown to have different
degrees of activation and phenotype in distinct tumor micro-
environments.34 Finally, conflicting results may be related to
different tumor types and to different clinical stages analyzed
in the distinct series.35
The statistically significant association observed in our
study between the chymase MCs count and gender (p 
0.001) has to be considered with caution. In fact, a large
difference between females and males (15% versus 85%) was
observed with our series of patients.
According to previously reported data,15 a significant
correlation was observed between histology and both overall
survival (p  0.02) and time to progression (p  0.02).
Patients with epithelioid histology showed better outcome in
comparison with sarcomatoid subtypes.
Moreover, a significant correlation was found between
histology and MVC (p  0.001). The observation that non-
epithelioid subtypes showed a significantly higher MVC than
those with epithelioid histology could be explained by con-
sidering that tumors with sarcomatoid differentiation have a
more aggressive behavior and the poorest prognosis.15
Although the data obtained in our study need to be
confirmed, they underline the importance of the immunologic
analysis in the prognostic and therapeutic approach in pa-
tients with pleural mesothelioma. New, tailored immunother-
apeutic trials in selected patients could represent a future step
in the treatment of this very aggressive and fatal tumor.
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